Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

PARIS, October 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP). NXL103 is a novel oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin, macrolide and quinolone resistant strains.

The NXL103 Phase II study was a double-blind, multinational, randomized, comparative study that evaluated this novel oral antibacterial as a treatment for mild to moderate CAP. The study recruited 300 adult patients in 9 countries in both the Northern and Southern hemispheres. Patients were randomised (1:1:1) to three treatment arms: 500mg of NXL103 twice a day, 600mg NXL103 twice a day or 1,000 mg of amoxicillin three times a day for 7 days. The key endpoints of the study were the clinical outcome in the clinically evaluable population at the early follow-up visit (7 to 14 days post-therapy) and safety. In this study, both doses of NXL103 were effective, with clinical response rates similar to those seen in the amoxicillin group. For the primary efficacy analysis, response rates were 91.4% in the 500mg NXL103 group; 94.7% in the 600mg NXL103 group; and 88.5% in the amoxicillin group. NXL103 was generally well tolerated with the most frequent adverse events related to gastrointestinal intolerance. There were no serious drug-related adverse events reported in the study.

The complete results from this Phase II trial will be published in the first half of 2009.

NXL103 has a spectrum of activity that indicates it has the potential to be effective in the treatment of skin and skin structure infections, includi
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Alere Inc. (NYSE: ALR ), ... Juliet Cunningham as Vice President, Investor Relations. ... for driving communications with the investment community. ... changes to increase shareholder value, it is critical that ... Nawana, Chief Executive Officer. "We are delighted that ...
(Date:11/21/2014)... 21, 2014  Tandem Diabetes Care ® , ... device company and manufacturer of the t:slim ® ... Tidepool, a non-profit dedicated to improving diabetes therapy ... that increases diabetes data accessibility. This partnership will ... currently under development, to download and access data ...
(Date:11/21/2014)... , Nov. 21, 2014  World Hemp Oil, an ... THC, announces they are now offering legal, organic oil ... Web type strains grown in medical marijuana states. People ... disorders, such as Parkinson,s, MS, and spinal cord injury, ... to pass, because imported CBD Oil Is legal in ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
(Date:11/24/2014)... Dallas, TX (PRWEB) November 24, 2014 ... ADP ribose polymerase (PARP) and is one of the ... genetically vulnerable to creating some types of melanoma, and ... but this also sometimes gives their malignancies a exclusive ... on PARP to fix their DNA and allow them ...
(Date:11/24/2014)... 2014 The typical American diet includes ... ingredients. Consistently consuming a diet high in calories and ... excess fat that typically accumulate around the internal organs ... ugly head in the form of love handles, beer ... the decision to rid themselves of the burden of ...
(Date:11/24/2014)... "My friend was killed when a ... the street in his motorized wheelchair," said an inventor ... came up with this idea so that people in ... developed the Safety Lites to make a wheelchair highly ... device ensures that motorists can see the wheelchair. This ...
(Date:11/23/2014)... Tbdress.com has recently announced that ... Nov. 28, 2014. The special offer will provide ladies many ... one of the world’s largest women’s dresses retailers, and its ... can enjoy great discounts on that day: Everything at Tbdress.com ... (for orders above $89). , People can use the following ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Locks-Magnetic.com, a ... emergency doors. Moreover, all the new products are available ... The marketing manager is proud of the new emergency ... reset automatically. And customers can choose from several colors. ... Buying high quality emergency door release is not as ...
Breaking Medicine News(10 mins):Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2
... red wine, grapes and other fruits, and similar in structure ... fat cells to develop, opening a door to a potential ... Kee-Hong Kim, an assistant professor of food science, and ... in this week,s issue of the Journal of Biological ...
... WEDNESDAY, April 4 (HealthDay News) -- Large amounts of ... doesn,t result in post-traumatic stress disorder -- boosts inflammation ... The findings are important because it,s known that ... to fare worse, according to the researchers at the ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, April ... to lengthen the lives of patients with a certain ... small phase 2 trial. The drug, belagenpumatucel-L (Lucanix), ... lung cancer and increased the five-year survival rate among ...
... Testing patients with non-small cell lung cancer for both ... may help to predict response to treatment with antifolates, according ... the AACR Annual Meeting 2012, held here March 31 - ... have KRAS gene mutations have a worse prognosis and do ...
... CHICAGO, IL (April 4, 2012)When combined with other treatments, ... growth of cancer cellshas been shown to extend survival ... Unfortunately, about 40 percent of colorectal cancer patientsspecifically ... called KRASdo not respond to the drug. Researchers ...
... To help foster the next generation of global health ... National Institutes of Health are building a network of ... and scientists with a significant mentored research experience in ... will be awarded over the next five years to ...
Cached Medicine News:Health News:Red wine, fruit compound could help block fat cell formation 2Health News:Witnessing, Experiencing Traumatic Events May Worsen Heart Disease 2Health News:Early Study Finds Some Promise for Lung Cancer Vaccine 2Health News:KRAS gene mutation and amplification status affects sensitivity to antifolate therapy 2Health News:Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 3
... Diana System consists of a set of ... main tests conducted in hospital immunohematology labs ... based advanced engineering solutions in robotics, fluidics ... quality of the monoclonal antibodies and the ...
... Resolution - Efficiently separates ... to 1000 bp. It ... PCR fragments, small DNA ... enzyme digestion, and double-stranded ...
... blood grouping reagents for use with ... system is a complete line of ... to determine blood groups in donors ... system includes a negative control for ...
... PK7200 works on patented microplate agglutination technology. ... system for donor ABO/Rh testing. PK7200 also ... and cytomegalovirus antibody detection. The Automated Microplate ... with the proven reliability that for the ...
Medicine Products: